Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).
Tonix Pharmaceuticals is a clinical-stage company dedicated to the development of novel pharmaceutical products that it believes will have broad societal impact, as they address medical conditions that are not well served by currently available therapies and represent large potential commercial opportunities. The company is focused in central nervous system (CNS) disorders and is developing therapies for the treatment fibromyalgia and posttraumatic stress disorder. Tonix expects to announce top-line clinical trial results for each of its two development programs in 2016.